19 June 2013
Keywords: month, delay, review, novartis, speedel, first-in-class, bp
Article | 22 December 2006
Swiss drug major Novartis says that the US regulatory review period has been extended by up to three months for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 December 2006
18 December 2006
© 2013 thepharmaletter.com